On November 17, Reuters reported that Johnson & Johnson announced it will acquire privately held oncology therapy research company Halda Therapeutics for $3.05 billion in cash . This acquisition aims to further expand Johnson & Johnson's business footprint in the treatment of solid tumors and prostate cancer.
Halda Therapeutics ' core drug candidate, HLD-0915, is currently in early to mid-stage development and is primarily intended for the treatment of prostate cancer. In addition to its core pipeline, the company has several early-stage experimental therapies for breast cancer, lung cancer, and other types of cancer, creating a highly complementary pipeline with Johnson & Johnson's oncology business.
It is worth noting that this is Johnson & Johnson 's second major acquisition this year.
In January of this year, Johnson & Johnson acquired Intra-Cellular Therapies , a neuropharmaceutical research and development company, for $14.6 billion , continuing to deepen its presence in key therapeutic areas.
Johnson & Johnson stated that the acquisition is expected to be completed within the next few months. Following the transaction, Halda's R&D resources and technology will be integrated into the Johnson & Johnson system, supporting its innovative breakthroughs and market expansion in the field of oncology treatment.

https://www.pharnexcloud.com/zixun/sx_111539